Bremelanotide (PT-141) boosted sexual desire and arousal satisfaction in premenopausal women with FSAD
Background
Female sexual arousal disorder (FSAD) is characterized by persistent inability to attain or maintain adequate genital lubrication and arousal during sexual activity, with limited pharmacological options at the time of study. Melanocortins are endogenous neuropeptides that modulate a range of physiological processes including sexual behavior, operating through centrally expressed receptors MC3R and MC4R. Alpha-melanocyte-stimulating hormone (α-MSH) is the endogenous ligand at these receptors, but its short half-life limits therapeutic utility. A synthetic, stable melanocortin analog capable of activating MC3R/MC4R centrally could address this unmet need by engaging the neural substrates of sexual desire that peripheral vasodilator therapies largely bypass.
Study Design
Bremelanotide 20 mg was administered intranasally as a single dose to 18 premenopausal women with a primary diagnosis of FSAD in a randomized, double-blind, placebo-controlled crossover design. Each subject completed two in-clinic sessions, receiving bremelanotide in one and matched placebo in the other. During each session, subjects viewed a 20-minute neutral video followed by a 20-minute sexually explicit video; vaginal photoplethysmography continuously monitored vaginal pulse amplitude as the primary physiological endpoint. Validated questionnaires assessed subjective perceptions of sexual desire, genital arousal, and satisfaction within the 24-hour post-treatment window.
Results
Subjective outcomes favored bremelanotide over placebo across multiple domains. More women reported moderate or high sexual desire following bremelanotide vs. placebo (p = 0.0114), representing the study's primary subjective endpoint. A trend toward more positive ratings of genital arousal feelings also emerged with bremelanotide (p = 0.0833), falling short of conventional significance but directionally consistent.
Among women who attempted sexual intercourse within 24 hours of treatment, significantly more reported satisfaction with their level of sexual arousal after bremelanotide compared with placebo (p = 0.0256).
Despite these subjective improvements, vaginal vasocongestion measured by vaginal photoplethysmography during erotic video viewing did not change significantly with bremelanotide relative to placebo, indicating a dissociation between central subjective response and peripheral genital blood flow under these laboratory conditions.
Key Findings
- More women reported moderate/high sexual desire with bremelanotide vs. placebo (p = 0.0114)
- Intercourse satisfaction with arousal level significantly higher post-bremelanotide vs. placebo (p = 0.0256)
- Trend toward improved genital arousal feelings with bremelanotide vs. placebo (p = 0.0833)
- Vaginal pulse amplitude during erotic video did not significantly differ between bremelanotide and placebo
- 18 premenopausal women with FSAD, single 20 mg intranasal dose, double-blind crossover design
Why It Matters
Bremelanotide's ability to improve self-reported desire and intercourse-related arousal satisfaction without requiring a physiological vasocongestion signal suggests its mechanism is primarily central — a meaningful clinical distinction from phosphodiesterase inhibitors and topical agents that target genital blood flow. For clinicians and researchers, this positions MC3R/MC4R agonism as a candidate pathway for the subjective-desire component of FSAD that prior peripheral therapies could not address. The intranasal single-dose crossover design also provides preliminary proof-of-concept timing data: effects were observable within a 24-hour window, relevant for at-home dosing protocols. The authors explicitly identify an at-home study as the next logical step, signaling that lab-context limitations may have suppressed the full physiological signal.
TitrateLab articles covering PT-141
Written by TitrateLab, separately from the study summarized above.
